Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Biotechnology

Healthcare
$8.44 +3.04%

+$0.26 today

Market cap
$547.12M
Beta
1.80
P/E (TTM)
-1.7
EPS (TTM)
-$5.11
52W Low $5.37High $17.58

Volume 2.36M

Average 1.24M

DNA Sales of Investments

Cash received from selling or redeeming investments.

Ginkgo Bioworks Holdings, Inc.NYSE: DNA

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments outflow grows to $108.18M

Q1 FY2026 sales of investments was $108.18M, compared with $0 a year earlier. Trailing-twelve-month sales of investments was $367.16M.

Context

  • Sales of investments amounted to 108.9% of revenue in FY2025, up 107.0 pp from a year earlier.
  • Sales of investments increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly sales of investments holds near $108.18M or moves back toward the trailing-twelve-month quarterly average of $91.79M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$108.18M-41.6% QoQ
Last fiscal yearDec 2025
$185.38M+4002.3% YoY
LTMMar 2026
$367.16M+8024.8% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+4002.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
185.38M USD
Year-over-year change
+4002.3%

Sales of Investments vs competitors

How DNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +8024.8% is the highest of 7, against a peer median of -8.9%.
  • Sales of investments amounts to 259.8% of revenue for DNA, versus a peer median of 35.0%.
DNA Competitors
Sales of Investments for DNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$1.07B USD-26.1%+50.6%1633.7%
ARVNArvinas, Inc.LTM Mar 2026$768.1M USD+1.4%-12.4%859.2%
REPLReplimune Group, Inc.LTM Dec 2025$367.56M USD-19.2%+14.7%—
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026$367.16M USD+8024.8%—259.8%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$291.5M USD+36.0%+207.1%—
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$262M USD-41.3%-8.5%69.1%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$223.03M USD+378.2%——
VALNValneva SELTM Mar 2026€1.39M EUR——0.9%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$0 USD——0.0%
MGTXMeiraGTx Holdings plcLTM Mar 2026$0 USD——0.0%
Peer median (excluding DNA) —-8.9%+14.7%35.0%

Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.84B)(2.11B)(892.87M)(547.03M)(312.76M)
Depreciation & Amortization29.08M42.55M71.55M63.02M58.99M
Deferred Income Tax30.21M(14.61M)(801K)(936K)(1.36M)
Stock-Based Compensation1.61B1.93B229.88M112.34M81.55M
Change in Working Capital(61.54M)(37.01M)29.84M(89.67M)(44.09M)
Accounts Receivables(114.09M)55.02M50.07M(4.73M)(1.47M)
Inventory(626K)164K000
Accounts Payables(2.25M)(10.84M)(1.18M)4.77M(2.99M)
Other Working Capital55.43M(81.35M)(19.05M)(89.72M)(39.62M)
Other Non-Cash Items(20.95M)(67.4M)266.9M142.69M46.62M
Operating Cash Flow(253.82M)(252.2M)(295.5M)(319.59M)(171.06M)
Capital Expenditures(56.52M)(52.27M)(40.8M)(62.54M)(7.67M)
Acquisitions (Net)(12.04M)26.65M(38.55M)(5.4M)0
Purchases of Investments(5M)(3.69M)00(418.63M)
Sales of Investments0004.52M185.38M
Other Investing Activities304K(38.08M)(1.34M)1.19M624K
Investing Cash Flow(73.26M)(67.39M)(80.69M)(62.24M)(240.29M)
Debt Repayment(1.12M)(1.24M)(1.3M)(897K)(354K)
Common Stock Issued099.3M080K19.47M
Common Stock Repurchased(25M)0(23K)00
Dividends Paid00000
Other Financing Activities1.56B(2.73M)(1.43M)(922K)(1.34M)
Financing Cash Flow1.53B95.34M(3.22M)(1.74M)17.78M
Effect of Forex Changes(19K)908K(588K)(281K)395K
Net Change in Cash1.21B(223.35M)(380M)(383.84M)(393.18M)
Free Cash Flow(310.34M)(304.47M)(336.3M)(382.13M)(178.72M)

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Intrinsic Alpha fair value

Locked

Current Price

$8.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.